FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer By Ogkologos - May 9, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CHECKMATE-8HW study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in... October 17, 2022 Embracing Bravery When You Have a Genetic Cancer Disease January 13, 2021 For Early-Stage Lung Cancer, Nivolumab and Chemo before Surgery Proves Effective May 20, 2022 Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... June 2, 2025 Load more HOT NEWS Five Questions With…Stephen. Majority of Patients With Cancer Are Willing To Be Vaccinated Against... Can Having Solar Panels or Living Near a Solar Farm Increase... Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump
